Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene RearrangementsTargeting Cancers with NRG1 Rearrangements

Overview of attention for article published in Cancer Discovery, February 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

news: 1 news outlet

twitter: 79 X users

Citations

dimensions_citation: 69 Dimensions

Readers on

mendeley: 60 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 2 news stories from 1 outlets.

Zenocutuzumab Generates Durable Responses in Advanced NRG1+ NSCLC

OncLive, 01 Nov 2023

Alison Schram, MD Zenocutuzumab (MCLA-128) elicited clinical activity with a tolerable safety profile in patients with advanced…

Clinical Trials Aim to Bring Zenocutuzumab to Patients with NRG1+ Cancers

OncLive, 22 Sep 2022

Blocking ligand interaction of HER2 and HER3 in patients with NRG1 fusion–positive tumors has demonstrated a clinically…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.